A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Clinical trial NCT06534983 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06534983
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-09
- Primary completion
- 2027-11-10
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.